Endocrinol Metab.  2016 Mar;31(1):142-146. 10.3803/EnM.2016.31.1.142.

Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves Disease

• Park S
• Kim TY
• Sim S
• Lim S
• Kim M
• Kwon H
• Jeon MJ
• Kim WG
• Shong YK
• Kim WB

• KMID: 2169705
• DOI: http://doi.org/10.3803/EnM.2016.31.1.142

Abstract

BACKGROUND
Thyrotoxic periodic paralysis (TPP) is a rare complication of thyrotoxicosis characterized by acute attacks of muscle weakness and hypokalemia. Recently, variation in several genes was suggested to be associated with TPP. This study evaluated the genetic predisposition to TPP in terms of the β2-adrenergic receptor (ADRB2), androgen receptor (AR), and γ-aminobutyric acid receptor α3 subunit (GABRA3) genes.
METHODS
This study enrolled 48 men with Graves disease (GD) and TPP, and 48 GD patients without TPP. We compared the frequencies of candidate polymorphisms between the two groups.
RESULTS
The frequency of the Gly16/Gly16 genotype in ADRB2 was not significantly associated with TPP (P=0.32). More CAG repeats (≥26) in the AR gene were not correlated with TPP (odds ratio [OR], 2.46; 95% confidence interval [CI], 0.81 to 8.09; P=0.08). The allele frequency of the TT genotype in the GABRA3 gene was not associated with TPP (OR, 1.83; 95% CI, 0.54 to 6.74; P=0.41).
CONCLUSION
The polymorphisms in the ADRB2, AR, and GABRA3 genes could not explain the genetic susceptibility to TPP in Korean men with GD.

Keyword

Periodic paralysis-hypokalemic; Polymorphism; ADRB2; Receptors, androgen; GABRA3

MeSH Terms

Gene Frequency
Genetic Predisposition to Disease
Genotype
Graves Disease*
Humans
Hypokalemia
Male
Muscle Weakness
Paralysis*
Receptors, Androgen
Thyrotoxicosis
Receptors, Androgen

Reference

1. Maciel RM, Lindsey SC, Dias da Silva MR. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol. 2011; 7:657–667.

2. Kung AW. Clinical review. Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 2006; 91:2490–2495.

3. Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore). 1992; 71:109–120.

4. Chen L, Lang D, Ran XW, Joncourt F, Gallati S, Burgunder JM. Clinical and molecular analysis of chinese patients with thyrotoxic periodic paralysis. Eur Neurol. 2003; 49:227–230.

5. Phakdeekitcharoen B, Ruangraksa C, Radinahamed P. Hypokalaemia and paralysis in the Thai population. Nephrol Dial Transplant. 2004; 19:2013–2018.

6. Ng WY, Lui KF, Thai AC, Cheah JS. Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. Thyroid. 2004; 14:187–190.

7. Kung AW, Lau KS, Fong GC, Chan V. Association of novel single nucleotide polymorphisms in the calcium channel alpha 1 subunit gene (Ca(v)1.1) and thyrotoxic periodic paralysis. J Clin Endocrinol Metab. 2004; 89:1340–1345.

8. Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab. 2002; 87:4881–4884.

9. Jongjaroenprasert W, Chanprasertyotin S, Butadej S, Nakasatien S, Charatcharoenwitthaya N, Himathongkam T, et al. Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population. Clin Endocrinol (Oxf). 2008; 68:646–651.

10. Kim TY, Song JY, Kim WB, Shong YK. Arg16Gly polymorphism in beta2-adrenergic receptor gene is not associated with thyrotoxic periodic paralysis in Korean male patients with Graves’ disease. Clin Endocrinol (Oxf). 2005; 62:585–589.

11. Kim WG, Kim TY, Kim JM, Rhee YS, Choi HJ, Kim WB, et al. CAG repeats in the androgen receptor polymorphism do not correlate with thyrotoxic periodic paralysis. J Korean Endocr Soc. 2008; 23:117–122.

12. Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves’ disease. Clin Endocrinol (Oxf). 2004; 60:719–725.

13. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992; 48:361–372.

14. Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ. 1991; 303:1096–1099.

15. Marx A, Ruppersberg JP, Pietrzyk C, Rudel R. Thyrotoxic periodic paralysis and the sodium/potassium pump. Muscle Nerve. 1989; 12:810–815.

16. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994; 33:9414–9419.

17. Leineweber K, Brodde OE. Beta2-adrenoceptor polymorphisms: relation between in vitro and in vivo phenotypes. Life Sci. 2004; 74:2803–2814.

18. Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia. 2003; 46:31–39.

19. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003; 26:76–83.